Healthcare
Live Price
Offline$33.57
+2.32% today
1Y Change
+134.76%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
UroGen Pharma Ltd. (URGN) is a Healthcare stock with a market cap of $1.12B and listed on NASDAQ. The stock last traded around $33.57 and up 134.8% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +21.4%, EPS growth of -7.8%, a dividend yield of 0.0%. What stands out right now is revenue +21.4%, EPS -7.8%, free cash flow -67.7% with operating margin -113.7% and ROIC -81.1%. Valuation already assumes a fairly strong business story at price/sales 10.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines URGN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
URGN
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
URGN Max Drawdown
-42.22%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for URGN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$48.0M
-25.4% YoY
FY Net Income
-$110.8M
-0.9% YoY
Free Cash Flow
-$85.6M
+2.5% YoY
Revenue Growth
+21.4%
EPS Growth
-7.8%
Gross Margin
88.7%
Net Margin
-139.8%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 110M | 90M | 83M | 64M | 48M |
| Gross Profit | 97M | 82M | 73M | 57M | 43M |
| Operating Income | -125M | -97M | -66M | -79M | -92M |
| EBITDA | -136M | -95M | -60M | -76M | -91M |
| Net Income | -153M | -127M | -102M | -110M | -111M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 111M | 172M | 95M | 55M | 44M |
| Total Assets | 200M | 286M | 178M | 136M | 120M |
| Total Liabilities | 306M | 295M | 244M | 225M | 111M |
| Shareholder Equity | -105M | -9M | -65M | -89M | 8M |
| Total Debt | 128M | 123M | 99M | 99M | 398K |
| Net Debt | 18M | -49M | 4M | 44M | -44M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
85M
+3.0% YoY
Capital Expenditures
752K
-196.1% YoY
Free Cash Flow
86M
+2.5% YoY
Key ratios
Gross Margin
88.7%
Operating Margin
-113.7%
Net Margin
-139.8%
ROE
170.2%
Debt / Equity
-1.22x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.